title: Anti-adipogenic effect of PDGF is reversed by PKC inhibition.
abstract: Healthy adipose tissue function depends on adipogenesis. The capacity to form new adipocytes prevents the emergence of insulin-resistant hypertrophied adipocytes, as well as the deleterious lipid deposition in muscle, liver, and pancreas. It is therefore important to understand how adipogenesis is modulated. Platelet-derived growth factor (PDGF) is anti-adipogenic, but the stage of differentiation that it targets, and the signaling pathways that it triggers, are not defined. We have studied the inhibitory effect of PDGF on murine 3T3-L1 preadipocyte and human preadipocyte differentiation. There was a significant attenuation in the protein expression of the adipogenic transcription factors, PPARgamma and C/EBPalpha, as well as in the levels of later differentiation markers, including adiponectin, aP2, and fatty acid synthase. PDGF treatment resulted in the persistence of PDGF receptor and PKCalpha expression, in contrast to the expected downregulation of both proteins that occurs during differentiation. Inactivation of conventional PKC isoforms, by bisindolylmaleimide I or PKC pseudosubstrate M20-28, partially reversed the inhibition of 3T3-L1 and human preadipocyte differentiation by PDGF, as assessed by fatty acid synthase expression and morphological appearance.
authors.affiliation: Ottawa Health Research Institute, Department of Medicine and Biochemistry, Microbiology & Immunology, University of Ottawa, Ottawa, Ontario, Canada.
authors.forename: Y
authors.initials: Y
authors.lastname: Artemenko
authors.forename: A
authors.initials: A
authors.lastname: Gagnon
authors.forename: D
authors.initials: D
authors.lastname: Aubin
authors.forename: A
authors.initials: A
authors.lastname: Sorisky
mesh_terms: D016475:3T3 Cells; D017667:Adipocytes / Q000166:cytology / Q000187:drug effects*; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D022762:CCAAT-Enhancer-Binding Proteins / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D008297:Male; D008301:Maleimides / Q000494:pharmacology; D051379:Mice; D008875:Middle Aged; D047495:PPAR gamma / Q000378:metabolism; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051571:Protein Kinase C-alpha; D017479:Receptors, Platelet-Derived Growth Factor / Q000378:metabolism; D013234:Stem Cells / Q000166:cytology / Q000187:drug effects*
chemical_list: D015415:Biomarkers; D022762:CCAAT-Enhancer-Binding Proteins; D004791:Enzyme Inhibitors; D007211:Indoles; D008301:Maleimides; D047495:PPAR gamma; D010982:Platelet-Derived Growth Factor; D017479:Receptors, Platelet-Derived Growth Factor; C496628:PRKCA protein, human; C496630:Prkca protein, mouse; D011493:Protein Kinase C; D051571:Protein Kinase C-alpha; C070515:bisindolylmaleimide I